Product Description
Aripiprazole is a medication that works in the brain to treat schizophrenia. It is also known as a second generation antipsychotic (SGA) or atypical antipsychotic. Aripiprazole rebalances dopamine and serotonin to improve thinking, mood, and behavior. (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Aripiprazole-(Abilify))
Mechanisms of Action: D2 Agonist, 5-HT1A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Otsuka
Company Location:
Company Founding Year: 1921
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Korea, New Zealand, Unknown Location
Active Clinical Trial Count: 9
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Bipolar Disorder|Schizophrenia
Phase 2: Autism Spectrum Disorder|Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12621001096842p |
2006-7041-83/hah | P2 |
Not yet recruiting |
Dermatitis, Atopic |
2023-07-20 |
|||
NCT03423680 |
APOLLO | P3 |
Recruiting |
Bipolar Disorder |
2025-11-01 |
45% |
2024-10-16 |
Primary Endpoints |
CTR20243723 |
CTR20243723 | P3 |
Completed |
Schizophrenia |
2025-10-24 |
2026-02-15 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2016-005111-40 |
2016-005111-40 | P2 |
Active, not recruiting |
Autism Spectrum Disorder |
2017-08-14 |
2025-06-29 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20212366 |
CTR20212366 | P1 |
Completed |
Schizophrenia |
2023-08-17 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20170309 |
CTR20170309 | P3 |
Recruiting |
Schizophrenia |
None |
2025-04-29 |
||
CTR20201480 |
CTR20201480 | P1 |
Completed |
Schizophrenia |
2023-08-17 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20170437 |
CTR20170437 | P1 |
Recruiting |
Schizophrenia |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20170432 |
CTR20170432 | P1 |
Recruiting |
Schizophrenia |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |